Catalog #SIM0014
InVivoSIM anti-human IL-6R (Tocilizumab Biosimilar)
Clone
Tocilizumab
Reactivities
Human
Product Citations
2
Isotype
Human IgG1
Product Description
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Tocilizumab making it ideal for research use. This Tocilizumab biosimilar reacts with human IL-6 receptor also known as CD126. IL-6R is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. IL-6R is expressed by activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6 receptor α chain binds IL-6 but requires association with gp130 to initiate signal transduction. Upon IL-6 binding the IL-6R complex influences antigen-specific immune responses, inflammatory responses, neuronal development, and is a major mediator of the acute phase reaction. Tocilizumab binds to both soluble and membrane bound IL-6R and blocks the binding of IL-6 to IL-6R.
Specifications
| Isotype | Human IgG1 |
|---|---|
| Recommended Isotype Control(s) | RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure pH 7.0 Dilution Buffer |
| Conjugation | This product is unconjugated. Conjugation is available via our Antibody Conjugation Services. |
| Immunogen | Human IL-6R |
| Reported Applications |
Functional assays ELISA |
| Formulation |
PBS, pH 7.0 Contains no stabilizers or preservatives |
| Endotoxin |
≤0.5EU/mg (≤0.0005EU/μg) Determined by LAL assay |
| Aggregation |
<5% Determined by SEC |
| Purity |
≥95% Determined by SDS-PAGE |
| Sterility | 0.2 µm filtration |
| Production | Purified from cell culture supernatant in an animal-free facility |
| Purification | Protein A |
| RRID | AB_2894735 |
| Molecular Weight | 150 kDa |
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
| Need a Custom Formulation? | See All Antibody Customization Options |
Product Citations
-
TNF-α induces type I IFN signalling to suppress neurogenesis and recruit T cells
In bioRxiv on 24 June 2025 by Nissen, T. A. D., Baig, A., et al.
-
Inflammatory arthritis immune related adverse events represent a unique autoimmune disease entity primarily driven by T cells, but likely not autoantibodies
In medRxiv on 6 June 2025 by Zhu, X., Yu, Y., et al.